Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Stake Boosted by Creative Planning

Creative Planning boosted its stake in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) by 35.8% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 15,640 shares of the biopharmaceutical company’s stock after buying an additional 4,120 shares during the period. Creative Planning’s holdings in Agios Pharmaceuticals were worth $695,000 as of its most recent SEC filing.

Several other large investors have also recently added to or reduced their stakes in the stock. Farallon Capital Management LLC increased its position in Agios Pharmaceuticals by 1.1% in the second quarter. Farallon Capital Management LLC now owns 5,654,502 shares of the biopharmaceutical company’s stock worth $243,822,000 after buying an additional 63,900 shares during the period. Vanguard Group Inc. increased its position in Agios Pharmaceuticals by 0.8% in the first quarter. Vanguard Group Inc. now owns 5,572,021 shares of the biopharmaceutical company’s stock worth $162,926,000 after buying an additional 44,583 shares during the period. Price T Rowe Associates Inc. MD increased its position in Agios Pharmaceuticals by 23.9% in the first quarter. Price T Rowe Associates Inc. MD now owns 2,012,993 shares of the biopharmaceutical company’s stock worth $58,861,000 after buying an additional 388,381 shares during the period. Marshall Wace LLP increased its position in Agios Pharmaceuticals by 307.8% in the second quarter. Marshall Wace LLP now owns 1,133,735 shares of the biopharmaceutical company’s stock worth $48,887,000 after buying an additional 855,739 shares during the period. Finally, BNP PARIBAS ASSET MANAGEMENT Holding S.A. increased its position in Agios Pharmaceuticals by 5.9% in the first quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 1,108,613 shares of the biopharmaceutical company’s stock worth $32,416,000 after buying an additional 62,153 shares during the period.

Agios Pharmaceuticals Trading Up 1.0 %

Shares of NASDAQ AGIO opened at $44.87 on Monday. Agios Pharmaceuticals, Inc. has a one year low of $20.40 and a one year high of $53.28. The firm has a market capitalization of $2.55 billion, a PE ratio of 3.95, a PEG ratio of 0.45 and a beta of 0.75. The business has a 50-day moving average price of $44.62 and a two-hundred day moving average price of $42.23.

Agios Pharmaceuticals (NASDAQ:AGIO) last announced its quarterly earnings data on Thursday, August 1st. The biopharmaceutical company reported ($1.69) EPS for the quarter, missing analysts’ consensus estimates of ($1.60) by ($0.09). Agios Pharmaceuticals had a negative return on equity of 3.81% and a net margin of 2,051.38%. The business had revenue of $8.60 million for the quarter, compared to analyst estimates of $9.34 million. During the same quarter in the previous year, the business posted ($1.51) earnings per share. The company’s revenue was up 28.4% compared to the same quarter last year. Research analysts anticipate that Agios Pharmaceuticals, Inc. will post 7.54 EPS for the current year.

Analyst Ratings Changes

A number of research analysts have recently commented on AGIO shares. Leerink Partners lowered Agios Pharmaceuticals from an “outperform” rating to a “market perform” rating and lowered their price target for the company from $60.00 to $56.00 in a report on Friday, September 27th. Scotiabank lifted their target price on Agios Pharmaceuticals from $51.00 to $53.00 and gave the stock a “sector outperform” rating in a report on Friday. StockNews.com lowered Agios Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Friday. Raymond James reiterated an “outperform” rating and issued a $51.00 price target on shares of Agios Pharmaceuticals in a research report on Thursday, October 10th. Finally, Royal Bank of Canada reiterated an “outperform” rating and issued a $55.00 price target on shares of Agios Pharmaceuticals in a research report on Friday. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and four have given a buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $52.33.

Insiders Place Their Bets

In other Agios Pharmaceuticals news, CFO Cecilia Jones sold 2,542 shares of the firm’s stock in a transaction dated Thursday, September 26th. The stock was sold at an average price of $49.03, for a total transaction of $124,634.26. Following the completion of the sale, the chief financial officer now directly owns 20,158 shares in the company, valued at approximately $988,346.74. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. In related news, CFO Cecilia Jones sold 2,542 shares of the company’s stock in a transaction on Thursday, September 26th. The shares were sold at an average price of $49.03, for a total value of $124,634.26. Following the completion of the sale, the chief financial officer now directly owns 20,158 shares in the company, valued at approximately $988,346.74. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, CEO Brian Goff sold 11,091 shares of the firm’s stock in a transaction dated Thursday, August 8th. The shares were sold at an average price of $42.75, for a total value of $474,140.25. Following the transaction, the chief executive officer now owns 78,792 shares in the company, valued at approximately $3,368,358. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 4.93% of the company’s stock.

Agios Pharmaceuticals Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.